Walleye Capital’s Olema Pharmaceuticals OLMA Stock Holding History

Walleye Capital’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$317K	Buy	+21,247	New	+$473K	﹤0.01%	3025
2025 Q2	–	Sell	-87,705	Closed	-$330K	–	4895
2025 Q1	$330K	Buy	87,705 +20,698	+31%	+$104K	﹤0.01%	2883
2024 Q4	$391K	Buy	+67,007	New	+$669K	﹤0.01%	3198
2024 Q2	–	Sell	-11,966	Closed	-$135K	–	5879
2024 Q1	$135K	Sell	11,966 -178	-1%	-$2.3K	﹤0.01%	4211
2023 Q4	$170K	Sell	12,144 -144,885	-92%	-$1.95M	﹤0.01%	3769
2023 Q3	$1.94M	Buy	+157,029	New	+$1.6M	0.01%	1763
2023 Q2	–	Sell	-182,337	Closed	-$633K	–	4728
2023 Q1	$633K	Buy	182,337 +151,036	+483%	+$616K	0.01%	1511
2022 Q4	$76.7K	Buy	+31,301	New	+$91.3K	﹤0.01%	2432
2022 Q2	–	Sell	-71,414	Closed	-$304K	–	2623
2022 Q1	$304K	Sell	71,414 -119,109	-63%	-$656K	0.01%	1305
2021 Q4	$1.78M	Buy	+190,523	New	+$3.95M	0.06%	359

Other funds holding OLMA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Walleye Capital's OLMA Position: Q1 2026 in Review

Walleye Capital opened a new position in Olema Pharmaceuticals (OLMA) in Q1 2026: 21,247 shares worth $317K. The stake represents ﹤0.01% of the portfolio and ranks #3025 among its holdings. This is a return to the name: Walleye Capital previously reported a position in OLMA as recently as Q1 2025.

Walleye Capital first reported a position in OLMA in Q4 2021 and has held it in 10 quarters since. The position peaked at $1.94M in Q3 2023. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

Walleye Capital held 21,247 shares of Olema Pharmaceuticals worth $317K as of Q1 2026.
Olema Pharmaceuticals was a new Walleye Capital position in Q1 2026.
Olema Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3025 holding.
Walleye Capital first reported a position in Olema Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
Walleye Capital's Olema Pharmaceuticals position peaked at $1.94M in Q3 2023.
195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.